Get the Stockscreener App
1.06
1.85%
-0.02
After Hours:
1.06
Soligenix Inc stock is traded at $1.06, with a volume of 130.63K.
It is down -1.85% in the last 24 hours and down -22.63% over the past month.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
See More
Previous Close:
$1.08
Open:
$1.09
24h Volume:
130.63K
Relative Volume:
0.46
Market Cap:
$10.69M
Revenue:
$960.60K
Net Income/Loss:
$-7.10M
P/E Ratio:
-0.1402
EPS:
-7.56
Net Cash Flow:
$-8.00M
1W Performance:
+1.92%
1M Performance:
-22.63%
6M Performance:
-58.59%
1Y Performance:
-53.91%
1-Day Range:
$1.04
$1.16
1-Week Range:
$1.04
$1.1844
52-Week Range:
$1.02
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
Name
Soligenix Inc
Sector
Industry
Phone
609-538-8200
Address
29 EMMONS DRIVE, PRINCETON
Compare SNGX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.06 | 10.89M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-20 | Downgrade | Dawson James | Buy → Neutral |
| Jan-31-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-14-17 | Reiterated | Maxim Group | Buy |
| Jul-17-17 | Initiated | H.C. Wainwright | Buy |
Soligenix Inc Stock (SNGX) Latest News
Soligenix Provides Shareholder Update on Rare Disease Pipeline - TipRanks
Soligenix (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options - Digital Journal
Soligenix Details Recent Progress and Upcoming Milestones - PR Newswire
Soligenix (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology - The Globe and Mail
Soligenix's (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach - Digital Journal
Exit Recap: Is Soligenix Inc a speculative investment2025 Short Interest & Weekly Top Stock Performers List - baoquankhu1.vn
Short Interest in Soligenix Inc. (NASDAQ:SNGX) Decreases By 12.5% - Defense World
Soligenix (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer - The Globe and Mail
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape - The Globe and Mail
Soligenix (NASDAQ: SNGX) Targets Critical Gaps in CTCL Treatment with HyBryte(TM) - Digital Journal
Soligenix Advances Novel Visible Light Therapy for Challenging Cutaneous T-cell Lymphoma - citybuzz -
Soligenix's HyBryte Therapy Shows Promise for Early-Stage Cutaneous T-Cell Lymphoma Treatment - citybuzz -
Soligenix Advances Novel Visible Light Therapy for Early-Stage Cutaneous T-Cell Lymphoma - MEXC
RiVax(R) Positions Soligenix (NASDAQ: SNGX) in Growing Biodefense Preparedness Efforts - Digital Journal
Soligenix Establishes At-The-Market Equity Offering Program - The Globe and Mail
Soligenix’s RiVax Vaccine Advances as Ricin Threats Highlight Biodefense Needs - citybuzz -
Soligenix enters sales agreement with Rodman - marketscreener.com
Soligenix Inc Enters Sales Agreement With Rodman - TradingView
Soligenix Enters At Market Issuance Sales Agreement - TradingView
Soligenix (NASDAQ: SNGX) Announces Positive Phase 2 Data for Rare Inflammatory Disease - Digital Journal
Soligenix’s SGX945 in Behcet’s disease published in Rheumatology (Oxford) - MSN
Soligenix Reports Positive Phase 2 Results for Behçet’s Disease Treatment - citybuzz -
Soligenix (NASDAQ: SNGX) Advances Solutions for Hard-to-Diagnose CTCL - The Globe and Mail
Soligenix Advances Novel Therapy for Hard-to-Diagnose Cutaneous T-Cell Lymphoma - citybuzz -
SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL… - MSN
Soligenix announces results from phase 2a trial of SGX302 - MSN
Soligenix Reaches Enrollment Milestone in Phase 3 FLASH2 Trial for HyBryte Treatment - citybuzz -
Soligenix (NASDAQ: SNGX) Reaches Enrollment Milestone in Phase 3 FLASH2 Trial for HyBryte(TM) - Digital Journal
San Gabriel Valley Tribune - FinancialContent
Can Soligenix Inc. stock double in next 5 years2025 Key Highlights & Low Volatility Stock Suggestions - Улправда
Can Soligenix Inc. stock maintain growth trajectory2025 Technical Overview & Consistent Profit Alerts - ulpravda.ru
Options Flow: Why Soligenix Inc. stock is trending among retail traders - Улправда
Is Soligenix Inc. (DOA0) stock a safe buy pre earnings2025 AllTime Highs & Growth Focused Entry Point Reports - ulpravda.ru
How Soligenix Inc. stock benefits from strong dollarPortfolio Value Summary & Daily Growth Stock Investment Tips - ulpravda.ru
Why Soligenix Inc. stock is trending among retail tradersTrade Entry Summary & Reliable Entry Point Trade Alerts - Улправда
CEO Moves: How strong is Soligenix Inc. stock balance sheetWall Street Watch & High Yield Equity Trading Tips - Улправда
Soligenix Completes Key Phase 2 Psoriasis Trial, Setting the Stage for SGX302 Data - TipRanks
Ideas Watch: Can Soligenix Inc stock double in next 5 yearsWeekly Trend Recap & Verified Momentum Stock Watchlist - moha.gov.vn
What drives Soligenix Inc DOA0 stock priceMerger & Acquisition Updates & Buy Sell Timing Alerts - earlytimes.in
Tech Rally: Is Soligenix Inc stock overvalued by current metricsLong Setup & Daily Technical Forecast Reports - moha.gov.vn
Soligenix (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat - Digital Journal
SNGX: Positive Results for Phase 2a Trial in Psoriasis - Research Tree
Soligenix publishes promising Phase 2a data for SGX945 in Behcet's Disease - Indian Pharma Post
Gains Recap: Will Soligenix Inc. (DOA0) stock issue positive guidanceJuly 2025 Market Mood & Free Verified High Yield Trade Plans - Улправда
Is Soligenix Inc. stock cheap at current valuationQuarterly Profit Summary & Smart Money Movement Tracker - Улправда
Alliance Global Partners Sticks to Its Buy Rating for Soligenix (SNGX) - The Globe and Mail
Will Soligenix Inc. (DOA0) stock issue positive guidanceJuly 2025 Summary & Growth Focused Entry Point Reports - Улправда
Institution Moves: Will Soligenix Inc. (DOA0) stock beat Nasdaq index returnsJuly 2025 PostEarnings & Daily Profit Maximizing Trade Tips - DonanımHaber
Soligenix Inc Stock (SNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):